Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
SPARTA
NCT03175224
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Scott Owen
Corneille Bashagaluke
514-934-1934 poste 34907
|
A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer
NeoCOAST-2
NCT05061550
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Jonathan Spicer
Nicola Raby
514-934-1934 poste 34095
|
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations
DESTINY-Lung04
NCT05048797
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Scott Owen
Nicola Raby
514-934-1934 poste 34095
|
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
TRUST-II
NCT04919811
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Scott Owen
Nicola Raby
514-934-1934 poste 34095
|
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ?50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
TROPION-Lung08
NCT05215340
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Benjamin Shieh
Nicola Raby
514-934-1934 poste 34095
|
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C
CodeBreaK 202
NCT05920356
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Benjamin Shieh
Nicola Raby
514-934-1934 poste 34095
|
Liquid biopsy for Non-Small Cell Lung Cancer: comparing plasma cell-free DNA/RNA to tissue NGS to assesses turnaround time, patient distress and cost-effectiveness
QC-LIQBIOP
n.d.
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Scott Owen
Nicola Raby
514-934-1934 poste 34095
|
Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab or Pembrolizumab With Histology-Specific Chemotherapy for Operable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
MK3475-A74
NCT04638582
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Jonathan Spicer
Nicola Raby
514-934-1934 poste 34095
|
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%
MK-2870-007
NCT06170788
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Jonathan Spicer
Nicola Raby
514-934-1934 poste 34095
|
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
MK-2870-009
NCT06305754
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Benjamin Shieh
|
Groupe d'étude en oncologie du Québec